Subscribe
Contact Us
About Us
Advertise
Home
News
News from MM&M
Off the Wire
Newsletters
PMD Profiles
Agency Creative Showcase
Publication Connection
PMD Marketplace
Careers
About Us
Additional Resources
MM&M
MM&M Jobs
MAHF
Voi Consulting
Advertise
Subscribe
Get Listed
Additional Resources
RSS
|
Login
|
Register
Regulatory
Abbott Receives U.S. FDA Approval for New Cataract Multifocal Intraocular Lens
March 10, 2010
Premium Lens Provides Medicare Beneficiaries With New Option
CSL Behring Receives FDA Approval of Hizentra™
March 04, 2010
First 20 Percent Subcutaneous Immunoglobulin Therapy
Novo Nordisk Receives FDA Approval for Norditropin(R) FlexPro(R) for Growth Hormone Treatment
March 03, 2010
Easy to use and simple treatment option for growth hormone disorders
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program
March 03, 2010
Phase 3 study did not meet main or secondary goals
FDA Approves Exalgo Extended-Release Tablets
March 02, 2010
CombinatoRx Achieves $40 Million Mil
Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
February 26, 2010
Company Announces New Enhancements to Patient Assistance Programs in the United States
Arena Pharmaceuticals Announces FDA Acceptance of Lorcaserin NDA for Filing
February 24, 2010
NDA is based on 18 clinical trials
FDA Advisory Committee Recommends Approval Of XIFAXAN® (rifaximin) Tablets, 550 Mg for Maintenance of Remission of Hepatic Encephalopathy
February 23, 2010
FDA has issued an action date of March 24, 2010
Forest Laboratories Receives Decision from FDA for Supplemental New Drug Application for Bystolic®
February 23, 2010
Additional indication not approved by FDA
Novartis Receives FDA Approval of Menveo(R), a Vaccine to Prevent Meningococcal Disease
February 22, 2010
Novartis plans to seek licensure of Menveo in infants and children 2-10 years of age
FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia
February 18, 2010
Approval Based on Data From Two of the Largest Trials Ever Conducted in Chronic Lymphocytic Leukemia
GlaxoSmithKline and XenoPort Receive FDA Complete Response Letter for Horizant (GSK1838262/XP13512) for RLS
February 17, 2010
US FDA Denies Approval of Horizant for RLS
Javelin Pharmaceuticals' Receives FDA PDUFA Date for Dyloject NDA
February 17, 2010
Filed NDA for Management of Acute Moderate-to-Severe Pain
FDA Approves Benicar(R) for the Treatment of High Blood Pressure in Children and Adolescents aged 6-16
February 11, 2010
New Treatment Option Available for the Rapidly Growing Population of Children Suffering From High Blood Pressure
Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval
February 08, 2010
Abbott's ARCHITECT human epididymis protein 4 (HE4) assay submitted for 510(k) clearance
Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study
February 08, 2010
Daniel K. Spiegelman Joins Board of Directors
XenoPort Announces Horizant as Brand Name for XP13512
February 04, 2010
FDA review of NDA for Horizant is February 9, 2010
FDA Approves Xiaflex for Debilitating Hand Condition
February 03, 2010
First drug to treat Dupuytren's contracture
Labopharm Receives FDA Approval For OLEPTRO(TM)
February 03, 2010
Second U.S. FDA Product Approval in Just Over a Year For Labopharm's CONTRAMID(R) Controlled Release Technology
FDA Accepts Javelin Pharmaceuticals' Submission and Files New Drug Application for Dyloject(TM)
February 02, 2010
Key Milestone in the Proposed Merger of Myriad Pharmaceuticals and Javelin Pharmaceuticals
Allergan, Inc. Announces FDA Approval of JUVÉDERM® XC Dermal Filler Formulated with Lidocaine
February 01, 2010
Approved to Last up to One Year from Initial Treatment
GSK's TYKERB(R) Receives Accelerated Approval for First-Line Combination Treatment of Metastatic Breast Cancer
January 29, 2010
TYVERB in European markets, is currently being reviewed by the EMEA for a comparable indication
Novo Nordisk's Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
January 26, 2010
A once-daily treatment that lowers blood sugar and does not promote weight gain
Spectrum Pharmaceuticals Announces Results of FDA Meeting Regarding FUSILEV® sNDA under Review for Advanced Metastatic Colorectal Cancer
January 25, 2010
No Additional Efficacy Studies Needed
Biogen Idec Issues Statement on U.S. Approval of AMPYRA (dalfampridine)
January 23, 2010
New Oral Therapy Addresses Key Need for MS Community
Somaxon Provides Update on New Drug Application for Silenor® for the Treatment of Insomnia
January 21, 2010
Resubmission has been filed, with 2 month review cycle
Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test
January 14, 2010
Abbott announces CE Mark (Conformite Europeene) certification for the ARCHITECT human epididymis protein 4 (HE4) test
Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R)
January 13, 2010
Milestone Marks Swiss Company's Entrance into the U.S. Blood Coagulation Market
Biogen Idec Submits Application in Europe for the Approval of Fampridine-PR Tablets to Improve Walking Ability in People with Multiple Sclerosis
January 12, 2010
Application for approval also submitted to Health Canada
FDA Approves ACTEMRA® (tocilizumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis (RA)
January 08, 2010
New treatment option available for patients with RA
Latest News
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
Abbott Receives U.S. FDA Approval for New Cataract Multifocal Intraocular Lens
Affymax® Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide in Japan
Alun Malone Joins Millennium Laboratories As New Business Development Executive
Lilly to Acquire European Rights to Pfizer Animal Health Assets
CSL Behring Receives FDA Approval of Hizentra™
EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Columbia Laboratories Enters into Purchase and Collaboration Agreement with Watson Pharmaceuticals for Progesterone Franchise
Novo Nordisk Receives FDA Approval for Norditropin(R) FlexPro(R) for Growth Hormone Treatment
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program
Most Popular
Most Emailed
Most Recent
Adamis Pharmaceuticals Signs Agreement to Acquire Prostate Cancer Drug Candidates
FDA Advisory Committee Recommends Approval Of XIFAXAN® (rifaximin) Tablets, 550 Mg for Maintenance of Remission of Hepatic Encephalopathy
Columbia Laboratories Enters into Purchase and Collaboration Agreement with Watson Pharmaceuticals for Progesterone Franchise
Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer
Arena Pharmaceuticals Announces FDA Acceptance of Lorcaserin NDA for Filing
FDA Approves Exalgo Extended-Release Tablets
Transdel Pharmaceuticals Appoints Terry Nida as Chief Business Officer
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program
Astellas Pharma Inc. Commences Tender Offer to Acquire All Outstanding Shares of OSI Pharmaceuticals for $52 per Share in Cash
Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
Novo Nordisk Receives FDA Approval for Norditropin(R) FlexPro(R) for Growth Hormone Treatment
FDA Advisory Committee Recommends Approval Of XIFAXAN® (rifaximin) Tablets, 550 Mg for Maintenance of Remission of Hepatic Encephalopathy
Affymax® Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide in Japan
Abbott Receives U.S. FDA Approval for New Cataract Multifocal Intraocular Lens
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
Lilly to Acquire European Rights to Pfizer Animal Health Assets
Alun Malone Joins Millennium Laboratories As New Business Development Executive
CSL Behring Receives FDA Approval of Hizentra™
Columbia Laboratories Enters into Purchase and Collaboration Agreement with Watson Pharmaceuticals for Progesterone Franchise
EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
Abbott Receives U.S. FDA Approval for New Cataract Multifocal Intraocular Lens
Affymax® Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide in Japan
Alun Malone Joins Millennium Laboratories As New Business Development Executive
Lilly to Acquire European Rights to Pfizer Animal Health Assets
CSL Behring Receives FDA Approval of Hizentra™
EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Columbia Laboratories Enters into Purchase and Collaboration Agreement with Watson Pharmaceuticals for Progesterone Franchise
Novo Nordisk Receives FDA Approval for Norditropin(R) FlexPro(R) for Growth Hormone Treatment
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program
Popular Topics
Acquisition
Agency
Animal Health
Biopharmaceutical
Biotech
Business
Clinical Management
Collaboration
Marketing & Communications
Medical Device
Medical Equipment
Merger
New Company
New Hire
New Hires
Personnel
Pharmaceutical
Pharmaceutical Marketplace
Pharmaceutical Products
Pipeline
Product Acquisition
Product Launch
Product Promotion
Regulatory
Research & Development